Nathaniel Chin, MD, medical director of the WRAP study, appeared on numerous Wisconsin news outlets to discuss the recent Food and Drug Administration (FDA) approval of a blood test for Alzheimer’s disease. The accuracy of the blood test was validated using data samples from the Wisconsin Alzheimer’s Disease Research Center (ADRC) and the Wisconsin Registry for Alzheimer’s Prevention (WRAP).
The blood test, known as the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, is for the early detection of amyloid plaques associated with Alzheimer’s disease in adult patients, aged 55 years and older, who are exhibiting signs and symptoms.
“It’s really because of the great Wisconsin participants that we now have something that’s pretty revolutionary,” Chin said to Fox6 News.
Implementation of the blood tests in clinics will take time and training for health care providers, he said. Ultimately, Chin described how early and accessible diagnosis could lead to benefits. “People can make lifestyle interventions — that would be exercising, sleep, diet, social engagement” based on these new tests, he said.
– Article by Caoilfhinn Rauwerdink
In the news
“Wisconsin plays part in FDA-approved Alzheimer’s blood testing” – Fox6 News, May 28, 2025
“UW-Health, UW-Madison helping with blood test to aid in diagnosing Alzheimer’s disease” – WBAY.com, May 28, 2025
“Wisconsin Alzheimer’s Institute contributes to FDA-approved blood test diagnosis” – WIFR, May 28, 2025.
“Madison woman hopes to take approved blood test after losing grandmother to Alzheimer’s disease” – WMTV, May 28, 2025
“UW Health aids FDA approval of Alzheimer’s blood test” – WFRV, May 29, 2025